In prostate and breast cancer, where sex steroids often drive tumor growth, GnRH agonists can effectively cease gonadotropin release and consequently suppress tumor progression by reducing the serum concentration of testosterone or estrogen to castrate levels [36,37]. This evidence concerns the gene GNRH1 and neoplasm.